Herpes Summary

Key Facts

  • Caused by HSV-1 or HSV-2
  • Lifelong latent infection
  • Recurrent episodes common
  • Asymptomatic shedding occurs

Transmission

  • Direct contact with lesions
  • Asymptomatic viral shedding
  • Sexual contact primary route
  • Autoinoculation possible

Diagnosis

  • Swab from lesion base
  • Viral culture or PCR
  • Type identification important
  • GUM specialist referral

First Episode

  • Aciclovir 200mg 5x/day
  • Start within 5 days
  • Continue 5-10 days
  • More severe than recurrences

Recurrent Episodes

  • <6 episodes/year: episodic
  • ≥6 episodes/year: suppressive
  • Self-initiated treatment option
  • Shorter duration than first episode

Complications

  • Superinfection
  • Urinary retention
  • Aseptic meningitis
  • Neonatal herpes

Genital Herpes

Infection with herpes simplex virus (HSV-1 or HSV-2) causing oral, genital and ocular ulcers with recurrent episodes

Pathophysiology & Transmission

Viral Characteristics

  • Caused by Herpes Simplex Virus (HSV-1 or HSV-2)
  • Following primary infection, virus becomes latent in local sensory ganglia
  • Recurrent episodes due to reactivation after latent period
  • Can cause symptomatic lesions or asymptomatic viral shedding

Transmission Routes

Primary Transmission

  • Acquired at mucosal surfaces or skin breaks
  • Direct contact with infected secretions
  • HSV-2: vaginal or anal intercourse
  • HSV-1: orogenital intercourse

Other Routes

  • Contact with lesions at other sites (eyes, fingers)
  • Non-mucosal surfaces (herpetic whitlow)
  • Autoinoculation to adjacent skin
  • Vertical transmission to neonate

Infectious Periods

  • Highest risk: when lesions present (vesicles, ulcers)
  • Lower risk: asymptomatic viral shedding
  • Shedding can occur without visible lesions
  • Transmission possible throughout infection

Clinical Features

First Episode

Lesion Characteristics

  • Multiple painful blisters
  • Quickly burst to form erosions/ulcers
  • Location: external genitalia, cervix, rectum, thighs, buttocks
  • Usually bilateral distribution
  • Develop 4-7 days after exposure

Systemic Symptoms

  • 50% report systemic symptoms:
  • Headache, fever, malaise
  • Dysuria
  • Tender inguinal lymphadenopathy
  • Duration: up to 20 days

Additional Features

  • Vaginal or urethral discharge
  • Local oedema
  • Tingling/neuropathic pain in genital area
  • Pain in lower back, buttocks, legs
  • Often more severe than recurrent episodes

Recurrent Genital Herpes

Key Features

  • Occur in same anatomical area
  • Prodromal symptoms: tingling/burning up to 48 hours before lesions
  • Less severe than initial episodes
  • Duration: 6-48 hours for symptoms
  • Lesions crust and heal in ~10 days
  • Systemic symptoms less common

Diagnosis & Differential Diagnosis

Diagnostic Approach

  • Refer to GUM specialist for confirmation
  • Swab from base of lesion (pop blister if necessary)
  • Tests: viral culture or PCR (depending on local arrangements)
  • Virus type identification important for prognosis/counseling

Differential Diagnosis

STI Ulcers

  • Syphilis: single, non-tender ulcer
  • Chancroid: single deep, painful ulcer
  • LGV: single/few ulcers + unilateral lymphadenopathy
  • Granuloma inguinale: painless, vascular ulcers

Other Infections

  • Herpes zoster (dermatomal distribution)
  • Scabies (burrows, intense itching)
  • Candida (erythema, satellite lesions)
  • Bacterial superinfection

Non-infectious Causes

  • Aphthous ulcers (fewer, larger lesions)
  • Skin disorders: dermatitis, psoriasis
  • Folliculitis, lichen sclerosus
  • Behçet's syndrome, Crohn's disease
  • Malignancy
  • Fixed drug eruptions

Management

Referral Recommendation

Ideally refer all suspected cases to GUM specialist for:

  • Accurate diagnosis
  • Comprehensive treatment
  • STI screening
  • Counselling and education
  • Appropriate follow-up

First Episode Treatment

Medication Dosage Duration Notes
Aciclovir 200 mg five times daily 5-10 days Start within 5 days of symptom onset
Valaciclovir 500 mg twice daily 5-10 days Alternative with better bioavailability
Famciclovir 250 mg three times daily 5-10 days Alternative option

Self-care Measures

Hygiene & Comfort

  • Clean with plain or salt water
  • Apply vaseline or topical anaesthetic
  • Increase fluid intake for dilute urine
  • Urinate in bath or with water flowing

Lifestyle Measures

  • Avoid tight clothing
  • Take adequate pain relief
  • Avoid sharing towels/flannels
  • Abstain from sexual contact until cleared

Recurrent Episode Management

Treatment Strategies

Episodic Treatment

  • For: <6 attacks per year
  • Aciclovir: 200mg 5x/day for 5 days
  • Consider self-initiated treatment
  • Start early in next attack
  • Shorter course than first episode

Suppressive Treatment

  • For: ≥6 attacks per year
  • Or: psychological distress
  • Or: affects social life
  • Aciclovir: 400mg twice daily
  • Duration: 6-12 months initially
  • Review annually for continuation

Antiviral Options for Recurrences

Regimen Episodic Therapy Suppressive Therapy
Aciclovir 200mg 5x/day × 5 days 400mg twice daily
Valaciclovir 500mg twice daily × 5 days 500mg once daily
Famciclovir 125mg twice daily × 5 days 250mg twice daily

Complications

Local Complications

  • Superinfection with Candida or Streptococci
  • Autoinoculation to fingers and adjacent skin
  • Secondary bacterial infection
  • Scarring and pigment changes

Neurological Complications

  • Autonomic neuropathy causing urinary retention
  • Aseptic meningitis during primary infection
  • Recurrent meningitis over months/years
  • Radiculopathy

Special Populations

  • Neonatal HSV: highest risk if maternal acquisition in third trimester
  • Immunocompromised: more severe, prolonged episodes
  • Pregnancy: risk of vertical transmission
  • HIV co-infection: more frequent recurrences

Prevention & Counseling

Key Counseling Points

  • Lifelong infection with recurrent episodes
  • Transmission risk even without symptoms
  • Condoms reduce but don't eliminate risk
  • Avoid sexual contact during prodrome/lesions
  • Inform partners about infection status
  • Suppressive therapy reduces transmission risk